Is AstraZeneca on track to meet its $80B revenue target?

AstraZeneca CEO Pascal Soriot aims for $80B annual sales by 2030; company on track with $58.7B in 2025, despite future loss of exclusivity for Brilinta, Soliris, and Farxiga. But it needs to find nine new blockbusters in the next five years.